Erschienen in:
13.05.2019 | Original Scientific Report
A Population-Based Study of Incidence, Presentation, Management and Outcome of Primary Thromboembolic Ischemia in the Upper Extremity
verfasst von:
Jørgen B. Vennesland, Kjetil Søreide, Jan Terje Kvaløy, Andreas Reite, Morten Vetrhus
Erschienen in:
World Journal of Surgery
|
Ausgabe 9/2019
Einloggen, um Zugang zu erhalten
Abstract
Objectives
To investigate the epidemiology of acute upper limb thromboembolism in a well-defined Norwegian population.
Methods
This study was a retrospective, single-center, observational population-based cohort study of acute upper limb thromboembolism. The study included all patients from the hospital’s primary catchment area from January 2000 to December 2015. Age- and gender-adjusted incidence rates were calculated using population demographics from Statistics Norway.
Results
A total of 54 patients were identified, of which 49 were included in the analyses: 27 (55%) females (median age 83 years, range 40–96) and 22 (45%) males (median age 70 years, range 42–95) (P = .053). The adjusted incidence rate for the period was 1.6 patients per 100,000 inhabitants per year (95% confidence interval 1.2–2.2) and did not change significantly during the period studied. Atrial fibrillation was detected by electrocardiography in 30 (61%) patients; in this group, 10 patients were on warfarin but only two had an international normalized ratio > 1.9 and the remaining 20 were not anticoagulated. Altogether, 38 (78%) patients underwent surgery, 1 (2%) was treated with thrombolysis, and the remaining patients were treated conservatively; no amputations were performed. Four patients (8%) died within 30 days, and 12 of the surviving 45 patients (27%) had recurrent thromboembolism.
Conclusion
The incidence rate was stable during the study period. Patients with upper limb thromboembolism due to atrial fibrillation were inadequately anticoagulated. One in four patients experienced a recurrent thromboembolic event. Lifelong anticoagulation should be considered in all patients with upper limb thromboembolism.